Chen, S, et al.
Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. Journal of Clinical Microbiology
1994; 32: 589.
Adams, DA, et al.
Reports of nationally notifiable infectious diseases – United States, 2011. Morbidity and Mortality Weekly Report
2013; 60: 1–117.
Blanco, JR, Oteo, JA. Human granulocytic ehrlichiosis in Europe. Clinical Microbiology and Infection
2002; 8: 763–772.
Petrovec, M, et al.
Human disease in Europe caused by a granulocytic Ehrlichia species. Journal of Clinical Microbiology
1997; 35: 1556–1559.
Arnež, M, et al.
First European pediatric case of human granulocytic ehrlichiosis. Journal of Clinical Microbiology
2001; 39: 4591–4592.
Bakken, JS, et al.
Clinical and laboratory characteristics of human granulocytic ehrlichiosis. Journal of the American Medical Association
1996; 275: 199–205.
Lotric-Furlan, S, et al.
Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia. Clinical Infectious Diseases
1998; 27: 424–428.
Heo, E, et al.
Serologic and molecular detection of Ehrlichia chaffeensis and Anaplasma phagocytophila (human granulocytic ehrlichiosis agent) in Korean patients. Journal of Clinical Microbiology
2002; 40: 3082–3085.
Park, J, et al.
Detection of antibodies to Anaplasma phagocytophilum and Ehrlichia chaffeensis antigens in sera of Korean patients by Western immunoblotting and indirect immunofluorescence assays. Clinical and Diagnostic Laboratory Immunology
2003; 10: 1059–1064.
Ge, Y, Rikihisa, Y. Identification of novel surface proteins of Anaplasma phagocytophilum by affinity purification and proteomics. Journal of Bacteriology
2007; 189: 7819–7828.
Ojogun, N, et al.
Anaplasma phagocytophilum outer membrane protein A interacts with sialylated glycoproteins to promote infection of mammalian host cells. Infection and Immunity
2012; 80: 3748–3760.
Mygland, A, et al.
EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. European Journal of Neurology
2010; 17: 8–16.
Stanek, G, et al.
Lyme borreliosis: clinical case definition for diagnosis and management in Europe. Clinical Microbiology and Infection
2011; 17: 79–79.
Oteo, JA, et al.
Presence of granulocytic ehrlichia in ticks and serological evidence of human infection in La Rioja, Spain. Epidemiology and Infection
2001; 127: 353–358.
Cizman, M, et al.
Seroprevalence of ehrlichiosis, Lyme borreliosis and tick-borne encephalitis infections in children and young adults in Slovenia. Wiener Klinische Wochenschrift
2000; 112: 842–845.
Cinco, M, et al.
Detection of HGE agent-like Ehrlichia in Ixodes ricinus ticks in northern Italy by PCR. Wiener Klinische Wochenschrift
1998; 110: 898–900.
Jenkins, A, et al.
Borrelia burgdorferi sensu lato and Ehrlichia sp. in Ixodes ticks from southern Norway. Journal of Clinical Microbiology
2001; 39: 3666–3671.
Lebech, AM, et al.
Immunoserologic evidence of human granulocytic ehrlichiosis in Danish patients with Lyme neuroborreliosis. Scandinavian Journal of Infectious Diseases
1998; 30: 173–176.
Zeman, P, et al.
Antibodies to granulocytic Ehrlichiae in the population of the western and central part of the Czech Republic [in Czech, English abstract available]. Epidemiologie, Mikrobiologie, Imunologie
2002; 51: 13–18.
Dvořáková, Heroldová M, Dvořáčková, M. Seroprevalence of Anaplasma phagocytophilum in patients with suspected Lyme borreliosis [in Czech, English abstract available]. Epidemiologie, Mikrobiologie, Imunologie
2014; 63: 297–302.
Hulínská, D, et al.
Detection of Borrelia, Anaplasma, Bartonella and Rickettsia spp. in ticks Ixodes ricinus from Prague parks in 2007 and 2008 [in Czech, English abstract available]. Zprávy Centra Epidemiologie a Mikrobiologie
2009; 18: 167–171.
Wormser, GP, et al.
The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis and babesiosis: clinical practice guidelines by the Infectious Disease Society of America. Clinical Infectious Diseases
2006; 43: 1089–1134.
Steere, AC, et al.
Prospective study of serologic tests for Lyme disease. Clinical Infectious Diseases
2008; 47: 188–195.
DeBiasi, RL. A concise critical analysis of serologic testing for the diagnosis of Lyme disease. Current Infectious Disease Reports
2014; 16: 450.
Lotrič-Furlan, S, et al.
Epidemiological, clinical and laboratory distinction between human granulocytic ehrlichiosis and the initial phase of tick-borne encephalitis. Wiener Klinische Wochenschrift
2002; 114: 636–640.
Fingerle, V, et al.
Human granulocytic ehrlichiosis in Southern Germany: increased seroprevalence in high-risk group. Journal of Clinical Microbiology
1997; 35: 3244–3247.
Pusterla, N, et al.
Serological evidence of human granulocytic ehrlichiosis in Switzerland. European Journal of Clinical Microbiology and Infectious Diseases
1998; 17: 207–209.
Unver, A, et al.
Western blot analysis of sera reactive to human monocytic ehrlichiosis and human granulocytic ehrlichiosis agents. Journal of Clinical Microbiology
2001; 39: 3982–3986.
Wormser, GP, et al.
Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. American Journal of Clinical Pathology
1997; 107: 142–147.
Horowitz, HW, et al.
Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. Clinical Infectious Diseases
2013; 56: 93–99.